By VETTAPHARMA reporter – Derek Roche: AstraZeneca reported that the U.S. Food and Drug Administration extended the review period for camizestrant, the company’s investigational next-generation oral selective estrogen receptor degrader (SERD), in ER-positive, HER2-negative advanced breast cancer.
The FDA extended the Prescription Drug User Fee Act (PDUFA) action date to allow additional time for review of the New Drug Application submitted for camizestrant, which is being evaluated for patients with advanced breast cancer harboring endocrine resistance-associated alterations.
The application is supported by data from the SERENA-2 Phase II trial, which evaluated camizestrant versus fulvestrant in previously treated ER-positive, HER2-negative advanced breast cancer. The study demonstrated improvements in progression-free survival and supported continued development of the molecule across multiple breast cancer settings.
Additional ongoing programmes include the SERENA-6 Phase III trial, assessing camizestrant in combination with CDK4/6 inhibitors in patients with emerging ESR1 mutations detected through circulating tumor DNA monitoring, aiming to delay disease progression through earlier therapeutic intervention.
Camizestrant represents part of AstraZeneca’s broader strategy of strengthening its breast cancer and precision oncology portfolio, particularly through targeted endocrine therapies and biomarker-driven treatment approaches.
For patients with endocrine-resistant breast cancer, the therapy may offer a potential oral treatment option designed to address resistance mechanisms that often limit long-term benefit from standard endocrine therapies.
From a commercial perspective, camizestrant remains an important late-stage oncology asset for AstraZeneca, with potential future growth tied to expansion across multiple breast cancer treatment settings and integration into precision medicine strategies targeting ESR1-mutated disease.
Quick FAQs:
1. Why did the FDA extend AstraZeneca’s camizestrant review timeline?
The FDA extended the review period to allow additional time for evaluation of AstraZeneca’s application for camizestrant in ER-positive, HER2-negative advanced breast cancer.
2. What is camizestrant being developed for?
Camizestrant is an investigational oral selective estrogen receptor degrader (SERD) being developed for patients with ER-positive, HER2-negative advanced breast cancer, particularly those with endocrine-resistant disease.
3. Which clinical trials support camizestrant development?
The programme is supported by the Phase II SERENA-2 trial and ongoing Phase III studies including SERENA-6, evaluating biomarker-guided treatment strategies in breast cancer.
4. What could camizestrant mean for breast cancer patients if approved?
If approved, camizestrant could provide an oral treatment option designed to address endocrine resistance and potentially improve disease control in advanced breast cancer patients with ESR1 mutations.
